Yuzu | $35,000,000 | (Apr 7, 2026)
Moonbounce | $12,000,000 | (Apr 7, 2026)
Insight Health AI, Inc. | $11,000,000 | (Apr 7, 2026)
Sudo Biosciences
United States
- Menlo Park, California
- 21/12/2023
- Series B
- $116,000,000
Sudo Biosciences is a biopharmaceutical company committed to designing and developing novel, best-in-class medicines to transform patients’ lives. Our lead programs target the tyrosine kinase 2 (TYK2) pseudokinase domain. TYK2 is a key mediator in cytokine signaling pathways that have been linked to a broad range of immune-mediated inflammatory conditions.
- Industry Biotechnology Research
- Website https://www.sudobio.com/
- LinkedIn https://www.linkedin.com/company/sudo-biosciences/
Related People
Scott ByrdFounder
United States -
Zionsville, Indiana
Professional experience includes cross-functional roles across multiple therapeutic areas in the pharmaceutical industry: marketing, corporate strategy, commercial strategy, clinical development strategy, sales, hospital product sales and marketing, corporate finance, engineering, and manufacturing.
Specialties: Pharmaceutical marketing, pharmaceutical sales, hospital marketing, hospital sales, marketing strategy, coporate strategy, finance, pharmaceutical pricing reimbursement and access, pharmaceutical launch experience, cardiovascular, critical care, infectious disease.
Ridge AI | $2,600,000 | (Apr 7, 2026)
NeuBird AI | $19,300,000 | (Apr 7, 2026)
Stipple Bio | $100,000,000 | (Apr 7, 2026)
Noon | $44,000,000 | (Apr 7, 2026)
Miravoice | $6,300,000 | (Apr 7, 2026)
Numos | $4,250,000 | (Apr 3, 2026)
Alien | $7,100,000 | (Apr 3, 2026)
EnerVenue | $300,000,000 | (Apr 3, 2026)
Monarch Quantum | $55,000,000 | (Apr 3, 2026)